Intravenous γ‐Globulin Treatment in Kawasaki Disease
Intravenous γ‐Globulin Treatment in Kawasaki Disease
复制标题
静脉注射γ-球蛋白治疗川崎病
DOI：
--
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
K. Harada
中科院分区：
文献类型：
--
作者：
K. Harada
进行了一项多中心随机对照研究，以评估不同剂量和种类的丙种球蛋白在川崎中的有效性。丙种球蛋白降低冠状动脉异常的发生率。γ-球蛋白的作用具有剂量依赖性。完整型比胃蛋白酶处理型更有效。为了确定γ-球蛋白的适应症，对既未接受γ-球蛋白也未接受吲哚美辛的患者进行了一项研究，这些患者在发病后9天内至少满足以下4项标准：（1）WBC：大于12，000/mm;（2）血小板计数：小于35×104γmm;（3）CRP：大于3 +;（4）Hct：小于35%;（5）白蛋白：低于3.5 g/dl（6）年龄：12个月或以下;（7）男性。这项前瞻性研究仍在继续。在143名儿童中，73.4%接受了γ-球蛋白，只有两名未接受γ-球蛋白的儿童表现出冠状动脉的小血管扩张。这些指南似乎可以令人满意地确定γ-球蛋白在川崎中的适应症。
A multicenter randomized controlled study was carried out to assess the effectiveness of different, doses and kinds of γ‐globulin in Kawasaki disease. Gamma globulin lowered the incidence of coronary artery abnormalities. The effect of γ‐globulin was dose dependent. The intact type was more effective than the pepsin treated type. To establish the indications for γ‐globulin, a study was made of patients who received neither γ‐globulin nor indomethacin and who, within nine days of onset of illness, satisfied at least four of the following criteria: (1) WBC: more than 12,000/mm; (2) platelet count: less than 35×104γmm; (3) CRP: more than 3 +; (4) Hct: less than 35%; (5) albumin: less than 3.5 g/dl (6) age: 12 months or less; (7) male sex. This prospective study is continuing. Of 143 children, 73.4% received γ‐globulin, and only two demonstrated small dilatations of the coronary arteries in children who did not receive γ‐globulin. These guidelines seem satisfactory to establish the indications for γ‐globulin in Kawasaki disease.
影响因子：
158.5
作者：
NEWBURGER, JW;TAKAHASHI, M;MELISH, ME
通讯作者：
MELISH, ME